

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)



(10) International Publication Number
WO 2023/156389 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61Q 19/10* (2006.01)
A61K 8/00 (2006.01) *A61P 13/06* (2006.01)
A61K 47/42 (2017.01)

(21) International Application Number:

PCT/EP2023/053647

(22) International Filing Date:

14 February 2023 (14.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22156843.9 15 February 2022 (15.02.2022) EP
22183172.0 05 July 2022 (05.07.2022) EP

(71) Applicant: **MERZ PHARMA GMBH & CO. KGAA**

[DE/DE]; Eckenheimer Landstrasse 100, 60318 Frankfurt
am Main (DE).

(72) Inventors: **EISELE, Karl-Heinz**; c/o Eckenheimer Land-

strasse 100, 60318 Frankfurt am Main (DE). **FINK, Klaus**;
c/o Eckenheimer Landstrasse 100, 60318 Frankfurt am
Main (DE). **TAYLOR, Harold V.**; c/o Eckenheimer Land-
strasse 100, 60318 Frankfurt am Main (DE). **JATZKE,**
Claudia; c/o Eckenheimer Landstrasse 100, 60318 Frank-
furt am Main (DE). **KÜHBACH, Katja**; c/o Eckenheimer
Landstrasse 100, 60318 Frankfurt am Main (DE).

(74) Agent: **WALLINGER RICKER SCHLOTTER TOST-**

MANN PATENT- UND RECHTSANWÄLTE PART-
NERSCHAFT MBB; Zweibrückenstraße 5-7, 80331 Mu-
nich (DE).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: LIQUID BOTULINUM TOXIN FORMULATION AND USE THEREOF

(57) Abstract: The present invention relates to a liquid formulation comprising (i) botulinum toxin, (ii) human serum albumin (HSA), and optionally (iii) a tonicity agent and/or (iv) a buffering agent. In one aspect, the liquid formulation is characterized by a very low iron ion concentration. In another aspect, liquid formulation is characterized by the absence or very low concentration of tryptophan and/or N-acetyl-tryptophan. According to the present invention, the liquid formulation can be prepared by a method comprising the steps of contacting human serum albumin with a chelating agent to obtain a mixture and removing the chelating agent from the mixture. Furthermore, the present invention relates to the use of the liquid formulation in the treatment of therapeutic indications and cosmetic conditions.



WO 2023/156389 A1